Article
Identifying EGFR mutations from SCLC patient plasma by mutant-enriched liquidchip technology.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University - 1 Jan 2000
Lu Hong-Yang, Lu Zhen-Yi, Cheng Qiao-Yuan, Cai Ju-Fen, Wang Xiao-Jia, Zhang Yi-Ping, Lou Cai-Jin, Yu Xin-Min, Qin Jing, Ye Wei-Wu, Lei Lei, Huang Jian, Yang Hui-Yi, Mao Wei-Min
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib are targeted drugs for the kinase domain of EGFR. They are widely used for the treatment of non-small cell lung cancer (NSCLC). The EGFR exon 19 deletion mutation and the L858R mutation in exon 21 comprise approximately 90% of the somatic mutations in NSCLC patients that respond to EGFR TKI....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.